

NCRI Cancer Conference

2 – 5 October 2005

Birmingham, U.K.

Programme

CME Accreditation

The conference has been approved by
The Federation of the Royal College of Physicians of the UK
for 23 external CPD credits



Event Programme

Sunday 2 October 2005

- 13.00 – 15.30 Workshops (various)
- 15.45 – 16.00 **Alex Markham** (NCRI Chairman)
Welcome address
- 16.00 – 16.30 **Jessica Corner (UK)**
The future research agenda: the perspective of people affected by cancer
- 16.30 – 17.10 **Rick Kaplan (UK)**
Perspectives on clinical research in the UK versus the US: where are we behind and where can we lead?
- 17.10 – 17.50 **Hugues de Thé (FRA)**
Modelling acute promyelocytic leukaemia pathogenesis through therapeutic response
- 17.50 – 18.30 **Adrian Harris (UK)**
New angiogenic pathways regulated by hypoxia
- 18.30 – 21.00 Opening Reception and Trade Exhibition

Monday 3 October 2005

- 08.45 – 09.00 **Tony Kouzarides (UK)**
Introduction
Jane Cope (UK)
Introduction to the NCRI
- 09.00 – 09.40 **William Kaelin (USA)**
The von Hippel-Lindau hereditary cancer syndrome: insights into oxygen sensing and cancer
- 09.40 – 10.20 **Malcolm Pike (USA)**
Chemoprevention of female cancers in premenopausal women: new targets and implementing what we already know
- 10.20 – 11.00 Coffee and Exhibition Viewing
- 11.00 – 11.40 **Hans Clevers (NED)**
Signalling pathways in the intestine
- 11.40 – 12.20 **Norman Coleman (USA)**
Molecular radiation oncology
- 12.20 – 15.00 LUNCH/Poster Session & Exhibition Viewing
- 15.00 – 17.15 Parallel Sessions
- 17.15 – 18.00 BREAK

18.00 – 18.40 **Sir David Lane (SNG)** – *The NTRAC Lecture*
Cyclin dependent kinases as targets for cancer therapy



18.40 – 19.20 **John Condeelis (USA)** – *The Institute of Cancer Research Lecture*
Discovery and characterisation of an invasion signature for mammary tumour cells



19.30 – 20.30 Civic Reception

20.30 Speakers' Dinner (By Invitation Only)

Tuesday 4 October 2005

09.00 – 09.40 **Mike Richards (UK)** – *The Hayman Lecture*
The contribution that research has made to the development of cancer strategy in the UK



09.40 – 10.20 **R n  Bernardis (NED)**
High throughput loss of function genetic screens to identify cancer-relevant genes

10.20 – 11.00 Coffee and Exhibition Viewing

11.00 – 11.40 **Patrick Johnston (UK)** – *The BACR Tom Connors Lecture*
Pharmacogenetics of colorectal cancer



11.40 – 12.20 **Sir Richard Peto (UK)**
UK cancer mortality trends – The hazards of smoking and benefits of stopping

12.20 – 15.00 LUNCH/Poster Session & Exhibition View

15.00 – 17.15 Parallel Sessions

17.15 – 18.00 BREAK

18.00 – 18.40 **Peter Jones (USA)**
Epigenetic therapy

18.40 – 19.20 **Karen Vousden (UK)**
Cell death or survival in response to p53


19.30 – 20.30 Drinks Reception

20.30 – 00.00 Conference Dinner & Party

Wednesday 5 October 2005

09.00 – 12.15 Parallel Sessions

CLOSE OF MEETING



PARALLEL SESSIONS

Monday 3rd October

Clinical - Breast Cancer

Hosted by: Bruce Ponder

- **Bruce Ponder (UK)**
The search for common predisposing genes
- **Kornelia Polyak (USA)**
The tumour microenvironment and its role in breast cancer
- **Mary Helen Barcellos-Hoff (USA)**
Emerging roles of TGFbeta in breast cancer
- **Andrew Tutt (UK)**
Novel therapy strategies for BRCA1 and BRCA2 associated cancers
- **Rob Clarke (UK)**
Isolation and characterization of human mammary stem cells

Consumer Interest - Information - Addressing Patients' Needs

Hosted by: Joanne Rule

- **Hilary Thomas (UK)**
Making links - information and the clinical trial
- **Speaker to be confirmed**
Macmillan Listening Study
- **Roy Grainger (UK)**
Patient information and peer review
- **Venetia Franglen**
Case Study – The SUIT Trial of the Impact of Providing Generic Information about Research to Adult Cancer Patients prior to their treatment decision
- **David Wright, Mary Sayers and Jenny Walton**
Collaborating with consumers in cancer research: Experience from the Macmillan Listening Study

Therapeutic Development - Developing Drugs Against Oncogenic Proteins

Hosted by: Paul Workman

- **Paul Workman (UK)**
Overview and Hsp90 molecular chaperone inhibitors
- **Tim Green (UK)**
Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530
- **Peter Parker (UK)**
Monitoring and targeting signal transduction pathways; EGFR and PI3Kinase
[click here to view the abstract](#)
- **Saïd Sebtì (USA)**
Thwarting Ras and STAT3 aberrant signal transduction circuits to battle cancer

- **Adam Sharp (UK)**
Novel chemical inhibitors of BAG-1 protein: protein interactions inhibit breast cancer cell growth and MAP kinase activity

Cancer Cell Biology - Epigenetics & Methylation

Hosted by: Wolf Reik

- **Wolf Reik (UK)**
Imprinting and epigenetic reprogramming in development and disease
- **Manuel Esteller (ESP)**
Title to be confirmed
- **Dirk Schubeler (SUI)**
Genome-wide and promoter specific analyses reveal sites of differential DNA methylation in normal and transformed human cells
- **Charlotte Bradbury (UK)**
Sodium valproate combined with all-trans retinoic acid shows clinical and biological activity in high risk acute myeloid leukaemia
- **Richard Bryant (UK)**
The polycomb group protein EZH2 promotes the proliferation and invasion of prostate cancer cells
- **Gordon Strathdee (UK)**
HOX gene family members are frequently inactivated by DNA methylation in human leukaemia

Cancer Cell Biology - Metastasis including Stromal Cell Tumour Interactions

Hosted by: Margaret Frame

- **Margaret Frame (UK)**
Calpain 2- and Src-dependence define a requirement for integrin turnover during distinct modes of tumour cell invasion
- **Peter Friedl (GER)**
Plasticity in cancer invasion: shifting integrin and protease requirements
- **Mikala Egeblad (USA)**
Title to be confirmed
- **Karin de Visser (NED)**
Inflammation-associated cancer development is B lymphocyte dependent
- **Erik Sahai (UK)**
In vivo imaging of squamous cell carcinoma invasion

Clinical - Modern Cancer Screening

Hosted by: Alan Ashworth

- **Emanuel Petricoin (USA)**
Use of the low molecular weight range circulatory proteome for biomarker identification: vision for combining with imaging modalities
- **Wendy Atkin (UK)**
A new NHS screening programme for bowel cancer screening: challenges and potential rewards
- **Julian Peto (UK)**
What cervical cancer screening did

- **Gareth Williams (UK)**
New markers for cancer detection
- **Jenny Donovan (UK)**
Evaluating prostate cancer treatment and the potential impact of screening: The Protect Trial and comparison arm

NCRI Clinical Study Group – Complementary Therapies (note: this parallel session will take place at 12:30 till 17:00)

Hosted by: Susie Wilkinson

12.30 – 12.40 **Susie Wilkinson**

Introduction

12.40 – 13.05 **Janet Richardson/Karen Pilkington**

Presentation by Research Council for Complementary Medicine

The long and winding road: Tracking down the evidence in CAM and cancer

Discussion

13.05 – 13.15 **Liz Thompson**

A randomised, double-blind, placebo controlled, clinical trial to assess the efficacy of the homeopathic medication Stomatect-spray in the prevention of chemotherapy-induced stomatitis in children

13.15 – 13.25 **Debbie Sharp**

The impact of relaxation and guided imagery training on the symptoms and quality of life in women with ovarian cancer undergoing chemotherapy: a randomised trial

13.25 – 13.35 **Kate Thomas**

The development and validation of a patient-centred outcome tool for use in cancer support care utilising complementary therapies

13.35 – 13.45 **Susie Wilkinson**

Helping with Touch or Talk (TOT). A multi-centre randomised controlled trial to examine the clinical and cost-effectiveness of cognitive behaviour therapy, aromatherapy massage and standard care for cancer patients with symptoms of depression and anxiety

13.45 – 13.55 **Speaker to be confirmed**

Prospective study of safety in acupuncture: patient and practitioner perspectives

13.55 – 14.10 **Liz Thompson**

Presentation 1 - Homeopathy for symptoms of oestrogen withdrawal in breast cancer survivors- a review of recent trials and the challenge of appropriate research methodologies for complex interventions

14.10 – 14.25 **University of Southampton**

Presentation 2 - Complementary and alternative therapy use among people undergoing cancer treatment

Discussion

14.25 - 14.40 **Debbie Sharp**

Presentation 3 - CAM use amongst male cancer patients: reasoned decision-making or 'clutching at straws'?

Discussion

- 14.40 – 14.55 **Edzard Ernst**
Presentation 4 - Ukrain – a new cancer cure? A systematic review of randomised clinical trials
Discussion
- 14.55 **Susie Wilkinson**
Conclusion/Discussion –

NCRI Clinical Study Group – Lung Cancer *(note: this parallel session will take place at 12:30 till 15:00)*

Hosted by: Tim Eisen

- 12.30 – 12.35 **Tim Eisen**
INTRODUCTION
- 12.35 – 12.45 **Tim Eisen**
Outcomes of the progress review and restructuring of the group
- 12.45 – 13.05 **Tim Eisen**
Current development and future priorities of the Mesothelioma sub-group
- 13.05 – 13.25 **Mike Peake**
Current development and future priorities of the Sceptre Sub-group
- 13.25 – 13.45 **John Field**
Current development and future priorities of the Translational Sub-group
- 13.45 – 14.05 **Allan Price**
Current development and future priorities of the NSCLC Stage I-III A SCLC LD Sub-group
- 14.05 – 14.25 **David Ferry**
Current development and future priorities of the NSCLC Stage IIIB/IV SCLC ED Sub-group
- 14.25 – 15.00 **Stephen Falk**
Current development and future priorities of the Rare Tumours Sub-group

NCRI Clinical Study Group – Testis Cancer

Hosted by: Robert Huddart

- 15.00 – 15.05 **Robert Huddart**
INTRODUCTION
- RESULTS OF CLOSED TRIALS**
- 15.05 – 15.30 **Speaker to be confirmed**
Final results of MRC TE08: A randomised trial of CT scan-frequency in Stage I NSGCT
- 15.30 – 16.00 **Robert Huddart**
Results of CR UK TE22 trial: A FDG PET in the prediction of relapse in stage I non-seminomatous germ cell tumour
- NEW RESEARCH / TRIAL IDEAS**
- 16.00 – 16.30 **Jonathan Joffe**
UK Management of stage I seminoma. Results of survey and proposals for national trial
- 16.30 16.55 **Jonathan Shamash (to be confirmed)**
Randomised trial – A randomised phase III study of short (30 minute) versus long (72 hour) infusion Bleomycin for patients with IGCCCG good prognosis germ cell tumours, TE3. A NCRI trial
- 16.55 – 17.00 **Robert Huddart**
An overview and discussion of the NCRI testis cancer portfolio

NCRI Clinical Study Group – Upper GI Cancer

Hosted by: David Cunningham

15.00 – 15.05 **David Cunningham**
INTRODUCTION

15.05 – 15.35 **John Neoptolemos**
Current national and international trials in Pancreatic Cancer –

15.35 – 16.05 **James Garden (UK)**
Current National Trials in Hepatobiliary cancer

16.05 – 16.35 **Tom Crosby (UK)**
Current Trials of Chemo-radiotherapy in Upper GI Cancer

16.35 – 17.15 **Bill Allum**
Current National Trials in Oesophago gastric Cancer

Prevention - Hormonal Manipulation

Hosted by: Valerie Beral

- **Tony Howell (UK)**
Anti-oestrogens and related therapies to prevent breast cancer
- **Henri Rochefort (FRA)**
Markers of response to ovarian hormones in early steps of human mammary carcinogenesis
- **Tim Key (UK)**
Endogenous hormones and cancer
- **Valerie Beral (UK)**
Potential for preventing cancer in women by hormonal manipulation

Supportive & Palliative Care - Improving the Management of Emotional Distress

Hosted by: Amanda Ramirez

- **David Kissane (USA)**
Improving clinical depression in advanced breast cancer: The Spiegel replication RCT
- **Michael Sharpe (UK)**
RCT of nurse led intervention for major depression
- **Susie Wilkinson (UK)**
RCT of aromatherapy in the management of anxiety and depression
- **Amanda Ramirez (UK)**
Poor mental health of cancer consultants

Tuesday 4th October

Clinical - Advances in Pancreatic Cancer

Hosted by: Nick Lemoine

Supported by Pancreatic Cancer Research Fund with CR-UK

- **David Tuveson (USA)**
Advances in modelling pancreatic cancer



- **Malte Buchholz (GER)**
The diagnostic microchip for pancreatic cancer
- **Tatjana Crnogorac-Jurcevic (UK)**
Molecular markers for pancreatic adenocarcinoma
- **John Neoptolemos (UK)**
Design and clinical applications of algorithms for early diagnosis
- **Margaret Tempero (USA)**
Novel therapeutics – the end of nihilism

British Oncological Association Session - Future Direction of Radiotherapy

Hosted by: Robert Coleman and Ros Eeles (*note: this parallel session will take place at 13:00 till 14:45*)



- **Norman Coleman (USA) BOA Lecture**
Future role of radiotherapy: the NIH view
- **Trevor Roberts (UK)**
The structure of national radiotherapy services for the year 2010
- **Peter Hoskin (UK)**
Radiotherapy trials in the UK – is this the renaissance?
- **Bleddyn Jones (UK)**
Proton treatment in the UK: Do we really need it?

[Click here for details of full session](#)

Consumer Interest - Trials to Treatment – should we be getting there quicker?

Hosted by: Frank Rhodes

- **Peter Littlejohns (UK)**
Developing new treatments faster – a research perspective
- **Paul Moss (UK)**
Title to be confirmed
- **Roger Wilson (UK)**
Case Study – The treatment of GIST

Cancer Cell Biology - DNA Repair

Hosted by: Stephen Jackson

- **Stephen Jackson (UK)**
The DNA-damage response: from molecular insights towards new approaches to anti-cancer therapy
- **Simon Boulton (UK)**
DNA double-strand break repair and cancer predisposition
- **Stephen West (UK)**
Homologous recombination and the maintenance of genome stability
- **Tomas Lindahl (UK)**
Strategies of repair of alkylated DNA
- **Christopher Mathew (UK)**
New genes and protein complexes link Faconi Anaemia to DNA repair

Clinical - Lung Cancer

Hosted by: Tim Eisen

- **Tim Eisen (UK)**
Title to be confirmed
- **Rafael Rosell (ESP)**
Predictive markers for customising and targeted therapies
- **Roman Thomas (USA)**
Genomic Approaches to Lung Cancer
- **Thomas Lynch (USA)**
Targeted Therapy of NSCLC: Role of EGFR TK mutations in selecting agents for treatments

NCRI Clinical Study Group – Colorectal Cancer

Hosted by: John Scholefield

- 13.30 - 13.35 **John Scholefield (UK)**
Welcome and introduction to the aims of this session
- 13.35 – 13.45 **John Scholefield (UK)**
Overview of current trials in portfolio
- HAVE NCRN TRIALS CHANGED PRACTICE?**
- QUASAR**
- 13.45 – 13.55 **Richard Gray (UK)**
What do the results mean?
- 13.55 – 14.05 **Rob Glynn-Jones (UK)**
What do they mean in terms of changing practice?
- CLASSIC**
- 14.05 – 14.15 **Philip Quirke (UK)**
What do the results mean?
- 14.15 – 14.25 **D Morton (UK)**
What do they mean in terms of changing practice?
- FOCUS**
- 14.25 – 14.35 **Matt Seymour (UK)**
What do the results mean?
- 14.35 – 14.45 **Will Stewart (UK)**
What do they mean in terms of changing practice?
- 14.45 – 15.00 Question and answer session
- 15.00 – 15.20 Tea/Coffee
- NEW TRIALS**
- 15.20 – 15.30 **John Primrose (UK)**
FACS relaunch
- 15.30 – 15.50 **Matt Seymour (UK)**
PICCOLO
- 15.50 – 16.05 **Rob Glynn-Jones (UK)**
CHRONICLE
- 16.05 – 16.15 Questions and answer session

NEW DEVELOPMENTS

- 16.15 – 16.25 **David Sebag-Montefiore (UK)**
Developments in Rectal Cancer
- 16.25 – 16.40 *What is happening in the Adjuvant Portfolio*
David Kerr (UK) (QUASAR 2)
Jim Cassidy (UK) (SCOT)
- 16.40 – 16.50 **Bob Steele (UK)**
New developments in prevention, screening and early diagnosis
- 16.50 – 17.00 **John Scholefield (UK)**
Closing remarks

NCRI Clinical Study Group – Head and Neck Cancer

Hosted by: Martin Robinson

- 15.00 – 15.05 **Martin Robinson (UK)**
Introduction

CURRENT TRIALS

- 15.05 – 15.05 **Martin Robinson (UK)**
MARCHON
- 15.15 – 15.25 **Catherine West (UK)**
MARCHON - TRANS
- 15.25 – 15.35 **Christopher Nutting (UK)**
PARSPORT and HOTTER
- 15.35 – 15.45 **Martin Birchall (UK)**
EASTER

THYROID

- 15.45 – 15.55 **Jayne Franklyn (UK)**
HILO
- 15.55 – 16.05 **John Buscombe (UK)**
Imaging in thyroid cancer

POSSIBLE NEW TRIALS

- 16.05 – 16.05 **J Brown (UK)**
Post-operative radiotherapy in head and neck cancer trial
- 16.15 – 16.25 **K McLennan (UK)**
Translational studies
- 16.25 – 16.35 **To be confirmed**
Palliative therapy proposal
- 16.35 – 16.45 **Professor McGurk (UK)**
Sentinel node biopsy study
- 16.45 – 17.00 **I Hutchinson (UK)** (SEND trial)
Speakers to be confirmed

NCRI Clinical Study Group – Melanoma / Renal Cancer

Hosted by: Martin Gore & Barry Hancock

12.30 - 13.00 **Tim Eisen (UK)**
Latest news on signal inhibition

13.00 – 13.30 **Robert Hawkins (UK)**
Enhancing host responses to immunotherapy

CURRENT TRIALS AROUND THE WORLD

13.30 – 13.45 **Dr David Chao (UK) / Professor Martin Gore (UK)**
Melanoma

13.45 – 14.00 **Emilio Porfiri (UK) / Professor Barry Hancock (UK)**
Renal Cancer

CURRENT TRIALS IN THE UK

14.00 – 14.15 **Martin Gore (UK)**
Melanoma

14.15 – 14.30 **Barry Hancock (UK)**
Renal Cancer

NCRI Clinical Study Group – Radiotherapy

Hosted by: Peter Hoskin

15.00 – 15.05 **Peter Hoskin (UK)**
Introduction

RADIOTHERAPY TRIAL UPDATE

15.05 – 15.20 **Christopher Nutting (UK)**
PARSPORT

15.20 – 15.35 **John Yarnold (UK)**
FAST/IMPORT (Physics)

15.35 – 15.50 **David Dearnaley (UK)**
RT01/CHIPP

15.50 – 16.05 **Peter Hoskin (UK)**
BNLI lymphoma dose trial

16.05 – 16.20 **D Talbot (UK)**
AQ4N

16.20 – 17.00 **Pat Price (UK)**
ACCORN

NCRN Clinical Trials Showcase

Hosted by: Rick Kaplan

Speakers to be confirmed



Clinical - Ovarian Cancer

Hosted by: Stan Kaye

- **Robert Brown (UK)**
Drug resistance in ovarian cancer: obstacle or target?
- **Hani Gabra (UK)**
Molecular profiling/gene expression analysis in ovarian cancer and potential for individualised treatment
- **Ian Jacobs (UK)**
NCRI screening trials
- **Stan Kaye (UK)**
Update on management of ovarian cancer, including novel approaches
[click here to view the abstract](#)
- **Julia Wilson (UK)**
Expression of the chemokine receptor CXCR4 alters the behaviour of ovarian cancer cells in vitro and in vivo

Clinical - Paediatric Oncology

Hosted by: Andy Pearson

- **Andy Pearson (UK)**
The challenges for clinical trials in childhood cancer and new drug development in the next 5 years
- **Javed Khan (USA)**
Inferring tumour progression models using array CGH data
- **Nazneen Rahman (UK)**
Aneuploidy-cancer predisposition syndromes - new insights into the links between the mitotic spindle checkpoint and childhood cancer development
- **AV Moorman (UK)**
Molecular cytogenetic characterisation of childhood acute lymphoblastic leukaemia (all) and correlation with outcome
- **Debbie Graham (UK)**
Mapping and analysis of tumour suppressor genes (TSGs) on chromosome 10q in childhood medulloblastoma
- **Aliki Taylor (UK)**
Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain

Prevention - General, including Screening and Vaccination

Hosted by: Valerie Beral

- **Charles Lacey (UK)**
Human Papillomavirus vaccines against cervical cancer
- **Andy Hall (UK)**
Primary liver cancer – prevention by vaccination & aflatoxin reduction
- **Sue Moss (UK)**
The potential of screening to prevent cancer deaths in the UK
- **Jane Wolstenholme (UK)**
The Economics of Cancer Screening

Cancer Cell Biology - Stem Cells

Hosted by: Fiona Watt

- **Sean Morrison (USA)**
Tumour suppressor genes regulate stem cell self-renewal
- **Fiona Watt (UK)**
Role of stem cells in epidermal tumour formation.
- **Dominique Bonnet (UK)**
Normal and leukaemic stem cells
- **Amanda Fisher (UK)**
Epigenetic profiles predict stem cell potency
- **Matthew Smalley (UK)**
Molecular dissection of the mouse mammary gland reveals a SCA-1-/CD49F- population which contains cells with stem cell ability

Supportive & Palliative Care - Improving Symptom Management and overall Patient Care

Hosted by: Lesley Fallowfield

- **Charles Cleeland (USA)**
Improving symptom management in patients with cancer
- **Galina Velikova (UK)**
Routine symptom assessment, subsequent communication and patient well being
- **Lesley Fallowfield (UK)**
Effective communication with patients who have cancer
- **Irene Higginson (UK)**
Title to be confirmed

Therapeutic Development - Tumour Suppressor Gene and Apoptosis Targets

Hosted by: Herbie Newell

- **Herbie Newell (UK)**
Overview of approaches to target tumour suppressor gene loss in cancer
- **Lyubomir Vassilev (USA)**
Small-molecule antagonists of the p53-MDM2 interaction: promising new agents for cancer therapy
- **Saul Rosenberg (USA)**
Novel antitumour agents that target the Bcl-2 family of anti-apoptotic proteins
- **Jean-Pierre Issa (USA)**
Title to be confirmed
- **Melanie Howell (UK)**
Pharmacological inhibition of NF- κ B selectively induces apoptosis in chronic lymphocytic leukaemia cells

Wednesday 5th October

Therapeutic Development - Angiogenesis

Hosted by: Adrian Harris

- **Roy Bicknell (UK)**
Identification of novel targets in the tumour vasculature; Robo4
- **Gordon Jayson (UK)**
Imaging angiogenesis
- **George Sledge, Jr (USA)**
Clinical development of VEGF-targeting agents
- **Robert Kerbel (CA)**
Markers and mechanisms for metronomic antiangiogenic chemotherapy
- **Emma Rennel (UK)**
VEGF 165b expression inhibits growth of human renal cell carcinomas xenotransplanted into nude mice
- **Carolyn Staton (UK) – (BACR Translational Research Award)**
Discovery and development of alphastatin, a novel anti-angiogenic and anti-vascular agent derived from humanfibrinogen

British Oncological Association Session – Integration of radiology in radiotherapy: the promise of image-guided treatment planning

Hosted by: Chris Nutting and Joe O'Sullivan



- **QS Ng (UK)**
Tumour anti-vascular effects of Radiotherapy (RT) combined with weekly combretastatin A4 Phosphate (CA4P) compared with RT alone
- **RA Sharma (UK)**
Yttrium-90 chemoradiation treatment of liver metastases from colorectal cancer: International phase I trial
- **MT Guerrero Urbano (UK)**
Results of Intensity Modulated Radioterapy (IMRT) in patients with locally advanced thyroid cancer: Report of acute toxicity
- **R Singhal (UK)**
Effect of cavity shaving on re-operation rate following breast conserving surgery
- **Marcel Van Herk (NED) - The Bob Champion Cancer Trust Lecture**
Image guided radiotherapy: current state of the art
- **Pat Price (UK)**
The application of functional imaging to radiotherapy planning
- **Christopher Nutting (UK)**
Current status and future role of IMRT

[Click here for details of full session](#)

- **Laurence Zitvogel (FRA)**
Immunopharmacology promoting NK cell activation for cancer therapeutics
- **Paul Moss (UK)**
Title to be confirmed
- **Neil Steven (UK)**
A novel non-viral transfection system for dendritic cells: results of a pilot trial of vaccination against melanoma antigens

Cancer Cell Biology - Infection and Cancer

Hosted by: Chris Boshoff

- **Max Parkin (UK)**
Cancer: the global contribution of infection
- **Alan Rickinson (UK)**
Immunotherapies for nasopharyngeal carcinoma and Hodgkin's disease
- **Diane Harper (USA)**
A vaccine for cervical cancer
- **Mary Kroll (UK)**
Trends in childhood leukaemia, Britain 1974-98
- **Andrea Varro (UK)**
Role of MMP-7 in epithelial-mesenchymal signalling
- **Seonaidh Cotton (UK)**
Lifestyle factors associated with high-risk HPV infection in women with cervical smear showing bordering nuclear abnormality
- **Seyyed Rezaee (UK)**
Suppression of inflammatory reactions by recombinant KSHV vOX-2:Fc protein

NCRI Clinical Study Group – Breast

Hosted by: Robert Coleman

“Endocrine manipulation for breast cancer prevention and treatment”

- 9.00 – 9.25 **Mitch Dowsett**
Targeting targeted therapy in breast cancer
- 9.25 – 9.50 **Ian Smith**
*Making the best use of aromatase inhibitors in operable breast cancer.
Current status and future questions*
- 9.50 – 10.15 **Chairs, speakers, Dan Rea and Robert Leonard**
Panel discussion
- 10.15- 10.45 *tea / coffee*
- 10.45 – 11.10 **Andrew Wardley**
*Breakthrough of the decade?
First results of Adjuvant and Neoadjuvant trials with trastuzumab (Herceptin)*

- 11.10 – 11.35 **Rob Stein**
Herceptin failure in advanced breast cancer: controversies and new clinical trials
- 11.35 – 12.00 **David Cameron**
Clinical approach to new treatment targets in breast cancer
- 12.00 – 12.15 **Chairs, speakers, Peter Canney**
Panel discussion

Prevention - Behaviour change

Hosted by: Jane Wardle

- **Jane Wardle (UK)**
Tackling the obesity epidemic
- **Robert West (UK)**
Projected national smoking prevalence and smoking-related death rates following actual and potential policy initiatives in the UK
- **Gary Whitlock**
Obesity and premature death: a prospective study of 500 000 men and 300,000 women
- **Peter Boyle (FRA)**
IARC and cancer control worldwide

Clinical - Prostate Cancer

Hosted by: David Neal

- **David Neal (UK)**
Clinical background to prostate cancer – potential areas for targeting current and future research
- **William Nelson (USA)**
Early initiation of prostate cancer – potential for chemoprevention
- **Val Macaulay (UK)**
The IGF axis as potential target for treatment of prostate cancer
- **Ian Mills (UK)**
Effects of a membrane trafficking protein on androgen response
- **Joe O'Sullivan (UK)**
A Phase 2 study of high activity Rhenium-186 HEDP with autologous peripheral blood stem cell transplant in progress hormone refractory prostate cancer metastatic to bone
- **Griet Vanpoucke (UK)**
Identification of mesenchymal genes involved in prostate development and carcinogenesis using serial analysis of gene expression (SAGE)

Cancer Cell Biology - Radiobiology

Hosted by: Gillies McKenna

- **John Thacker (UK)**
The influence of DNA repair genes on radiation sensitivity and genetic stability in mammals
- **Gillian Tozer (UK)**
Tumour vasculature as a target for treatment
- **Gillies McKenna (USA)**
Signal transduction targets for modifying radiation responses
- **A Chalmers (UK)**
DNA repair mechanisms underlying the radiosensitising effects of chemical inhibitors of PARP-1
- **Kaye Williams (UK) - (BACR/AZ Young Scientist Frank Rose Award)**
Combining HIF-1 targeted approaches with conventional anti-cancer treatments

WORKSHOPS

Sunday 2nd October

NCRI Cancer Informatics Initiative Workshop

Co-Chairs: Richard Begent and Ken Buetow

- 13.00 – 13.45 **Alex Markham**
(Chair, NCRI Informatics High Level Steering Committee, UK)
Introduction and Welcome
- 13.15 – 13.45 **Ken Buetow**
(Director of NCICB and caBIG programme, USA)
Cancer Informatics
- 13.45 – 14.15 **Sir Mike Brady**
(Principal Investigator, e-DiaMoND project, UK)
Medical Imaging
- 14.15 – 14.45 **Carlos Caldas**
(Principal Investigator, CancerGRID project, UK)
CancerGRID - A Demonstrator for the NCRI Informatics Initiative
- 14.45 – 15.00 **Richard Begent**
(Chair, NCRI Informatics Task Force, UK)
Title to be confirmed

Molecular Targeting in Cancer

(Sponsored by: The Cancer Recognised Research Group in Northern Ireland and The Research and Development Office of the HPSS NI)

Joint chairs: Stephanie McKeown and Paddy Johnston

- 13.00 – 13.45 **Keynote lecture:**
Steve Jackson
The Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, UK.
“Molecular targeting in cancer: lessons from the field of DNA repair”
- 13.45 – 14.00 **Timothy R Wilson, Wendy L Allen, Ultan McDermott, Miranda McEwan, Leona Galligan and Patrick G Johnston, Daniel B. Longley.**
Drug Resistance Group, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, N. Ireland.
c-FLIP: a new target for colon cancer?
- 14.00 – 14.15 **Andrea Valentine, Hayley McKeen, Helen O. McCarthy, Kerry McAlpine, Keeva McClelland, David G. Hirst, Tracy Robson.**
Molecular Therapeutics Group, School of Pharmacy, Queen’s University Belfast, Belfast, N.Ireland.
Characterisation of a novel HSP90 interacting protein, FKBP-L/DIR1; implications for pathways controlling cell growth and survival.
- 14.15 – 14.30 **Luciano A. Guerreiro Lucas^{1,2}, Christopher A. Mitchell¹, Paul Barber², Keyi Jiang³, Gerald A. Soff³, Gillian M. Tozer².**
1 Centre for Molecular Biosciences, University of Ulster, Coleraine, N. Ireland;

2 Gray Cancer Institute, Northwood, London, UK;

3 Northwestern University, Chicago, IL, USA.

Molecular targeting of angiogenesis - an intravital imaging study.

14.30 – 14.45 **Christopher J Watson¹, Hugh O’Kane¹, Perry Maxwell^{1,2}, Kate E. Williamson¹**

1 Uro-Oncology Research Group, Department of Pathology, Queen’s University Belfast, Northern Ireland

2 Royal Hospitals Trust, Belfast, N. Ireland.

In vitro and in vivo evidence that mitomycin-c chemotherapy up-regulates the death receptor Fas in bladder cancer cells.

14.15 – 15.00 General discussion

15.00 Tea / coffee

[Click here for related Abstracts](#)

Wednesday 5th October

Supportive and Palliative Care - Interactive Workshop on Communicating about Randomised Control Trials

Hosted by: Lesley Fallowfield

Speakers to be confirmed

Workshop on Cancer Associated Thrombosis 12.30 – 2pm

Chairmen: Michael Peckham, London Stan Kaye, London

12.15 – 12.45 **Collect Japanese lunch-box**

12.45 – 12.50 **Michael Peckham**

Introduction:

12.50 – 13.20 **A.K. Kakkar**

Prevention and treatment of VTE in cancer

13.20 – 13.40 **A Young**

Catheter associated thrombosis

13.40 – 13.55 **Questions**

13.55 – 14.00 **Stan Kaye**

Closing remarks.

Translational Research in Clinical Trials Workshop

Hosted by: Peter Parker

Supported by CR-UK TRICC in association with NTRAC

- **Arul Chinnaiyan (USA)**
The success story: from trial samples to clinical data
- **Doug Altman (UK)**
The reality check: statistics and samples
- **Emanuel Petricoin (USA)**
Proteomics for clinical applications and molecular medicine

- **Phil Quirke (UK)**
Trials, imaging and pathology
- **James Brenton (UK)**
Clinical significance of functional genomics

Workshop Panel:

– At last the clinical trial is in place – but what samples should I collect and what should I do with them?

Hosted by: Carlos Caldas

[Click here for details of full session](#)